ArticleNordic journal of psychiatry2017
A pharmacodynamic modelling and simulation study identifying gender differences of daily olanzapine dose and dopamine D2-receptor occupancy.
Article in Nordic journal of psychiatry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Reinforcement of Self-Regulated Brain Activity in Schizophrenia Patients Undergoing Rehabilitation.BioMed research international · 2021Trial
- Sex-specific effects of the atypical antipsychotic risperidone on performance in a risky decision-making task.Behavioural brain research · 2027Article
- Biomaterials Empowering in New Era of Women's Healthcare System.Reproductive sciences (Thousand Oaks, Calif.) · 2026Review
- Sex Differences in Psychotropic Drug Exposure and Safety: A Systematic Review Toward Personalized Dosing Strategies.Journal of personalized medicine · 2026Review
- The Impact of Sex and Age on Antipsychotic Serum Concentrations.Schizophrenia bulletin · 2026Article
- Sex dimorphism controls dysbindin-related cognitive dysfunctions in mice and humans with the contribution of COMT.Molecular psychiatry · 2024Article
- Gender differences in cognitive improvements after two months of atypical antipsychotic treatment in first episode schizophrenia.Frontiers in psychiatry · 2024Article
- Psychosis brain subtypes validated in first-episode cohorts and related to illness remission: results from the PHENOM consortium.Molecular psychiatry · 2023Article
- Women with Schizophrenia-Spectrum Disorders After Menopause: A Vulnerable Group for Relapse.Schizophrenia bulletin · 2023Article
- The Effect of Menopause on Antipsychotic Response.Brain sciences · 2022Review
- Breast cancer in schizophrenia could be interleukin-33-mediated.World journal of psychiatry · 2021Review
- Sex Differences in Dopamine Receptors and Relevance to Neuropsychiatric Disorders.Brain sciences · 2021Review
- Gender differences in the use of atypical antipsychotics in early-onset schizophrenia: a nationwide population-based study in Brazil.BMC psychiatry · 2021Article
- Estrogens in schizophrenia: progress, current challenges and opportunities.Current opinion in psychiatry · 2021Review
- Resting-State Functional Connectivity of the Ageing Female Brain-Differences Between Young and Elderly Female Adults on Multislice Short TR rs-fMRI.Frontiers in neurology · 2021Article
- The Pharmacodynamics of Antipsychotic Drugs in Women and Men.Frontiers in psychiatry · 2021Review
- Head-to-Head Comparison of Sedation and Somnolence Among 37 Antipsychotics in Schizophrenia, Bipolar Disorder, Major Depression, Autism Spectrum Disorders, Delirium, and Repurposed in COVID-19, Infectious Diseases, and Oncology From the FAERS, 2004-2020.Frontiers in pharmacology · 2021Article
- The clinical course of schizophrenia in women and men-a nation-wide cohort study.NPJ schizophrenia · 2020Article
- Association of sleep among 30 antidepressants: a population-wide adverse drug reaction study, 2004-2019.PeerJ · 2020Article
- Individualized medicine: Sex, hormones, genetics, and adverse drug reactions.Pharmacology research & perspectives · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundGender differences in treatment response rates for patients treated with antipsychotics are known. However, the literature lacks a pharmacodynamic model to allow for gender-based clinical trial simulations from modelling parameters for Olanzapine and dopamine D2 receptor occupancy. Thus, the primary aim of this analysis is to test and quantify the effect of gender on the pharmacodynamics of Olanzapine.
methodsPopulation pharmacodynamic modelling was performed using non-linear mixed effects modelling in MONOLIX, while the Clinical Trial Simulations were performed using R for statistical programming. The pharmacometric analysis is based on a pooled data approach from three clinical studies where patients were diagnosed with schizophrenia and one clinical study where the patients were diagnosed with bipolar disorder.
resultsOlanzapine D2RO was modelled using an E
conclusionThe pharmacometrics analysis and model-based dosing simulations suggest that, in order to achieve 70% D2RO, women require a 10 mg/day dose and men require approximately a 20 mg/day dose of Olanzapine. Further, clinical implications exist suggesting that clinicians should factor patient gender when considering both a starting dose, as well a, a maintenance dose for patients prescribed Olanzapine due to quantifiable gender-differences of striatal dopamine D2 receptor occupancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.